The Times Australia
Google AI
Health

.

Ivermectin is still not a miracle cure for COVID-19, despite what you may have read

  • Written by Andrew McLachlan


The head lice drug ivermectin has yet again been touted in the media as a possible treatment for COVID-19. But despite the favourable headlines, huge uncertainty remains about whether this treatment can be safely and effectively repurposed to tackle the coronavirus.

In recent weeks the media has been awash with claims ivermectin, when given in combination with the common antibiotic doxycycline and zinc supplements, is effectively a “cure” for COVID-19.

Yet there has been no definitive clinical trial so far showing this is the case. All we have are observational studies and clinicians’ opinions.

The World Health Organisation’s database of clinical studies for COVID-19 shows there are currently 16 trials investigating ivermectin. Even these studies are unlikely to provide the high-quality data necessary to show ivermectin can actually provide its touted benefits.

Get your news from people who know what they’re talking about.

Many of the current studies have low numbers of participants, weak study designs, and inconsistent (and relatively low) ivermectin dosing regimes, with ivermectin frequently given in combination with other drugs.

The Royal Australian Council of General Practitioners and the Australian Commission for Quality and Safety in Health Care have warned there is insufficient evidence ivermectin is a safe and effective treatment for people infected with the coronavirus.

What do we know about ivermectin for COVID-19?

Laboratory studies using monkey cells in a test tube (as opposed to clinical studies in human patients) have shown ivermectin can shut down the replication of SARS-CoV-2, the coronavirus that causes COVID-19, within 24-48 hours of exposure to the drug.

Ivermectin is thought to inhibit the virus by preventing viral proteins moving in and out of the host cell’s nucleus, which is essential for replication of the coronavirus.


Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it


The problem is this process requires very high concentrations of ivermectin – well above the recommended dose for humans. This means ivermectin’s virus-killing powers would be unlikely to be harnessed inside the human body.

A detailed analysis of the relationship between dose and concentration of ivermectin suggests none of the currently used ivermectin dosing regimens would deliver high enough concentrations of ivermectin inside the body to activate its virus-killing effects.

Another review backs this up, suggesting all of the ivermectin doses being investigated in current clinical trials would fall well short of achieving drug concentrations high enough to wipe out SARS-CoV-2.

Even a 120 mg dose of ivermectin, which would be regarded as excessive (compared with the recommended dose of 3-15mg for treating parasitic infections) resulted in blood concentrations several orders of magnitude times lower than those needed to inhibit the virus.

Head louse on human hair
Great for killing head lice, but the jury’s still out on coronavirus. GillesSM/Wikimedia Commons, CC BY-SA

How much ivermectin is too much?

While ivermectin generally doesn’t cause problematic side effects at the currently used doses, there is limited information about whether much larger doses would also be safe.

Repurposing ivermectin as a “cure” for COVID-19 would require massive doses, which would substantially increase the risk of side effects such as nausea, rash, dizziness, immune suppression, abdominal pain, fever, raised heart rate and unstable blood pressure.

Ivermectin at usual doses does not enter the central nervous system, but after large doses of the drug it may enter the brain, potentially causing impaired vision, hampering the central nervous system (which could in turn affect breathing, heart rate and consciousness), and exaggerating the effects of other sedative medicines such as benzodiazepines.


Read more: Tested positive for COVID-19? Here's what happens next – and why day 5 is crucial


Ivermectin is a hugely useful medicine in treating parasitic illnesses such as lice, worms and scabies, particularly in developing countries. But as we have already seen in the case of the malaria drug hydroxychloroquine, just because a medicine is useful for one purpose, it cannot automatically be considered a miracle cure for COVID-19.

Repurposing drugs as COVID-19 treatments

Repurposing existing drugs as possible COVID-19 treatments is a smart strategy, but requires several key principles to be addressed. The drug must have antiviral effects in cells and animals at doses relevant to humans. The drug must be able to get to the site of infection in the body (or reduce the inflammation associated with the infection). It is best if the antiviral mechanism is understood. And finally, well designed clinical trials are needed to be sure the drugs works in people with the infection and it is safe to use (especially in older, vulnerable unwell people).

Thankfully, Australia’s National COVID-19 Clinical Evidence Taskforce continually assesses and updates the best evidence-based advice for treating COVID-19, which you can read here.

This article first appeared in The Conversation. It was republished with permission.

Times Magazine

Epson launches ELPCS01 mobile projector cart

Designed for the EB-810E[1] projector and provides easy setup for portable displays in flexible ...

Governance Models for Headless CMS in Large Organizations

Where headless CMS is adopted by large enterprises, governance is the single most crucial factor d...

Narwal Freo Z Ultra Robotic Vacuum and Mop Cleaner

Rating: ★★★★☆ (4.4/5)Category: Premium Robot Vacuum & Mop ComboBest for: Busy households, ha...

Shark launches SteamSpot - the shortcut for everyday floor mess

Shark introduces the Shark SteamSpot Steam Mop, a lightweight steam mop designed to make everyda...

Game Together, Stay Together: Logitech G Reveals Gaming Couples Enjoy Higher Relationship Satisfaction

With Valentine’s Day right around the corner, many lovebirds across Australia are planning for the m...

AI threatens to eat business software – and it could change the way we work

In recent weeks, a range of large “software-as-a-service” companies, including Salesforce[1], Se...

The Times Features

AI could help us more accurately screen for breast cancer – new research

At least 20,000[1] Australian women are diagnosed with breast cancer each year. And more than ...

Housing ACT tenants left in unsafe conditions

An ACT Ombudsman report has found that Housing ACT tenants have been left waiting in unsafe and haza...

Shark SteamSpot S2001 Review: A Chemical-Free Way to Tackle Messes and Stubborn Stains

If you're looking for a reliable steam mop that can handle both everyday spills and stubborn stains ...

How Businesses Are Generating Profits in a High-Inflation Economic Environment

Inflation in Australia and globally has surged to multi-decade highs since 2021, driven by pande...

The Effects of the War in the Middle East on Australian Small Businesses

The war in the Middle East is not a distant geopolitical event for Australia. In an interconnect...

Back at uni? How to help your wellbeing while you study

University can be a time of great opportunities, but it can also be very stressful[1]. Many stud...

Taste Port Douglas celebrates 10 years of world-class flavour in the tropics

30+ events, new sunrise and wellness experiences, 20+ chefs and a headline Michelin-star line-up...

Oztent RV tent range. Buy with caution

A review of the Oztent RV "30 second tent" range. Three years ago we bought an RV-4 from BCF Mack...

Essential Upgrades for a Smarter, Safer Australian Home

As we settle into 2026, the concept of the "dream home" has fundamentally shifted. The focus has m...